Tags : NAVIFY Tumor Board 2.0

Roche and GE Healthcare Launch NAVIFY Tumor Board 2.0 for

Tuba Khan May 31, 2019

Shots: The NAVIFY Tumor Board 2.0 with medical imaging capabilities brings a personalized treatment in patients with cancer with its initial availability in the US & Canada The tumor board […]readmore

Tags : NAVIFY Tumor Board 2.0

Roche and GE Healthcare Launch NAVIFY Tumor Board 2.0 for

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : NAVIFY Tumor Board 2.0

﻿Roche and GE Healthcare Launch NAVIFY Tumor Board 2.0 for

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Roche and GE Healthcare Launch NAVIFY Tumor Board 2.0 for